A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)

Trial Profile

A Phase II Study of MK-3475 in Patients With Advanced Merkel Cell Carcinoma (MCC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Aug 2017

At a glance

  • Drugs Pembrolizumab (Primary)
  • Indications Merkel cell carcinoma
  • Focus Therapeutic Use
  • Sponsors Merck
  • Most Recent Events

    • 11 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 05 Apr 2017 Results assessing the presence of Merkel cell polyomavirus as predictor of response to pembrolizumab, presented at the 108th Annual Meeting of the American Association for Cancer Research
    • 20 Apr 2016 Interim results (n=26) presented at the 107th Annual Meeting of the American Association for Cancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top